Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. MaxCyte Inc. shares valued at $66,788 were sold by Ross Thomas M. on Feb 02. At $5.77 per share, Ross Thomas M. sold 11,575 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Also, Doerfler Douglas sold 10,665 shares, netting a total of over 61,537 in proceeds. Following the sale of shares at $5.77 each, the insider now holds 333,197 shares.
Before that, Doerfler Douglas had sold 19,335 shares from its account. In a trade valued at $110,016, the President and CEO traded MaxCyte Inc. shares for $5.69 each. Upon closing the transaction, the insider’s holdings decreased to 19,335 shares, worth approximately $1.53 million.
Analysts at William Blair started covering the stock with ‘”an Outperform”‘ outlook in a report released in late August. As of August 24, 2021, Wedbush has initiated its “an Outperform” rating for MXCT. Earlier on August 24, 2021, Stifel initiated its rating. Their recommendation was “a Buy” for MXCT stock.
Analyzing MXCT Stock Performance
On Wednesday, MaxCyte Inc. [NASDAQ: MXCT] rose 4.55% to $4.60. The stock’s lowest price that day was $4.375, but it reached a high of $4.71 in the same session. During the last five days, there has been a surge of approximately 3.84%. Over the course of the year, MaxCyte Inc. shares have dropped approximately -15.75%. Shares of the company reached a 52-week high of $6.02 on 01/31/23 and a 52-week low of $4.32 on 03/07/23. A 50-day SMA is recorded $5.15, while a 200-day SMA reached $5.48. Nevertheless, trading volume fell to 0.52 million shares from 0.28 million shares the previous day.
Support And Resistance Levels for MaxCyte Inc. (MXCT)
According to the 24-hour chart, there is a support level at 4.41, which, if violated, would cause prices to drop to 4.23. In the upper region, resistance lies at 4.75. The next price resistance is at 4.90. RSI (Relative Strength Index) is 42.01 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.15, which suggests the price will decrease in the coming days. Percent R is at 58.82%, indicating low price movement. Stochastics %K at buying indicates that the stock is to be held.
Is MaxCyte Inc. subject to short interest?
Stocks of MaxCyte Inc. saw a sharp rise in short interest on Jan 12, 2023 jumping by 80000.0 shares to 1.85 million. Data from Yahoo Finance shows that the short interest on Dec 14, 2022 was 1.77 million shares. A jump of 4.32% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.75 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.75.
Which companies own the most shares of MaxCyte Inc. (MXCT)?
In terms of MaxCyte Inc. share price expectations, FactSet research, analysts set an average price target of $11.81 in the next 12 months, up nearly 172.73% from the previous closing price of $4.40. Analysts anticipate MaxCyte Inc. stock to reach $14.00 by 2023, with the lowest price target being $9.00. In spite of this, 7 analysts ranked MaxCyte Inc. stock as a Buy at the end of 2023. On August 24, 2021, Stephens assigned a price target of “an Overweight” to the stock and initiated coverage with a $19.